Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M688Revenue $M25.1Net Margin (%)-774.1Altman Z-Score-9.6
Enterprise Value $M1,013EPS $-1.4Operating Margin %-615.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-774.7Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.1Cash flow > EarningsY
Price/Sales23.45-y EBITDA Growth Rate %--Current Ratio2.1Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-59.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M196ROIC % (ttm)-156.6Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EXELFirst Eagle Investment 2014-06-30 Sold Out $3.22 - $3.8
($3.45)
$ 3.512%Sold Out0
EXELFirst Eagle Investment 2014-03-31 Reduce-0.01%$3.38 - $8.24
($6.84)
$ 3.51-49%Reduce 65.91%400,000
EXELFirst Eagle Investment 2012-09-30 Add0.02%$4.28 - $6.45
($5.29)
$ 3.51-34%Add 422.58%1,175,800
EXELFirst Eagle Investment 2012-03-31 Add$4.49 - $6.47
($5.14)
$ 3.51-32%Add 125.00%225,000
EXELFirst Eagle Investment 2011-12-31 Buy $3.95 - $7.81
($5.01)
$ 3.51-30%New holding100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
($7.34)
$ 3.51-52%Sold Out0
EXELFirst Eagle Investment 2011-03-31 Sold Out $7.22 - $12.45
($9.89)
$ 3.51-65%Sold Out0
EXELFirst Eagle Investment 2010-12-31 Buy 0.01%$3.98 - $9.08
($5.66)
$ 3.51-38%New holding280,000
EXELFirst Eagle Investment 2009-12-31 Sold Out -0.02%$5.33 - $8
($6.86)
$ 3.51-49%Sold Out0
EXELFirst Eagle Investment 2009-09-30 Buy 0.02%$4.4 - $6.99
($5.65)
$ 3.51-38%New holding274,700
EXELFirst Eagle Investment 2009-06-30 Sold Out -0.01%$4.16 - $5.55
($4.88)
$ 3.51-28%Sold Out0
EXELFirst Eagle Investment 2009-03-31 Reduce$4.32 - $5.85
($4.8)
$ 3.51-27%Reduce 25.67%144,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARCHESI VINCENT TDirector 2014-09-17Buy20,000$1.71101.17 view
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.15-33.2 view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.68-26.5 view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.72-27.12 view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.39-21.64 view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.13-32.94 view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-59.53 view
RIVERA LUPE MEVP, Operations 2010-12-15Sell75,000$7.5-54.13 view
Schwab GiselaEVP & Chief Medical Officer 2010-12-09Sell4,112$6.5-47.08 view
WILLSEY LANCEDirector 2010-09-07Buy36,200$3.6-4.44 view

Quarterly/Annual Reports about EXEL:

News about EXEL:

Articles On GuruFocus.com
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 

More From Other Websites
Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog Jul 02 2015
10 Best Biotech Stocks in the NASDAQ Jul 01 2015
EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jul 01 2015
Exelixis Provides Update on Genentech’s Pending New Drug Application for Cobimetinib, an... Jul 01 2015
Biotech Stock Mailbag: Exelixis, Puma Bio Jun 26 2015
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary Jun 25 2015
Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape Jun 22 2015
Watch These 10 Stocks Over The Weekend Jun 20 2015
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer Jun 07 2015
ASCO Reaffirms Why I'm Holding Exelixis Jun 05 2015
Notable option activity in equities Jun 01 2015
6 Key Cancer Winners From ASCO Presentations Jun 01 2015
Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in... May 31 2015
Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR... May 31 2015
Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the... May 30 2015
Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the... May 30 2015
EXELIXIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK